Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website http://www.thejh.org

Original Article

Volume 4, Number 1, March 2015, pages 131-136


Prognostic Utility of Transforming Growth Factor Beta-1 in Diffuse Large Cell Non-Hodgkin Lymphoma

Figures

Figure 1.
Figure 1. Two-year overall survival curve of patients with diffuse large cell non-Hodgkin lymphoma.
Figure 2.
Figure 2. Two-year disease-free survival curve of patients with diffuse large cell non-Hodgkin lymphoma.

Tables

Table 1. Patient Characteristics
 
VariablesNo.Percentage %
Age (18 - 60 years) (mean ± SD: 44.5 ± 10.7 years)50100%
Sex
  Male3264%
  Female1836%
Clinical stage
  I, II2346%
  III, IV2754%
Performance status
  ≥ 21122%
International prognostic index
  Low risk1734%
  Intermediate low risk1326%
  Intermediate high risk1122%
  High risk918%
Extra nodal sites
  ≤ 13876%
  > 11225%
Clinical presentation
  Lymphadenopathy3968%
  Splenomegaly2652%
  Hepatomegaly1836%
  Anemia2346%
  B symptoms2448%
Laboratory investigation
  LDH
    Normal1428%
    Elevated3672%
  Uric acid
    Normal3468%
    Elevated1632%
  TGF-β1
    Before treatment (mean ± SD: 14.7 ± 6.)50100%
    After treatment (mean ± SD: 6.3 ± 5.8)50100%
  Hepatitis markers
    HCV1224%
    HBV12%
    HCV + HBV36%
Response
  Complete response (CR)4284%
  Partial response (PR)48%
  No response (NR)48%

 

Table 2. Correlation Coefficient Between Transforming Growth Factor Beta-1 and Other Variable in Patients Groups
 
VariablesTransforming growth factor beta-1
rP value
IPI: international prognostic index.
Clinical stage+0.6*0.008
Bulky disease+0.8*0.006
Patient response+0.2*0.03
IPI+0.3*0.04

 

Table 3. Multivariate Analysis for Survival
 
VariableDisease free survivalOverall survival
P valueHR95% CIP valueHR95% CI
CI: confidence interval; PFS: progression-free survival; HR: hazard ratio; OS: overall survival.
Age0.570.80.4 - 1.70.830.90.2 - 1.7
Performance status ≥ 20.033.41.10.750.80.3 - 2.4
Elevated LDH0.860.10.5 - 2.40.730.80.3 - 2.5
TGF-β10.0073.51.4 - 8.90.0035.81.8 - 18.8
B symptoms0.530.70.2 - 2.20.130.20.02 - 1.6
Clinical stage0.431.40.6 - 3.30.271.90.6 6.3
Bulky disease0.0083.71.5 - 9.10.0045.91.9 - 8.9